Pan-Cancer Proteomic and Transcriptomic Meta-Analysis of PD-1/PD-L1 Signaling Reveals Predictive Biomarkers for...

Area of Science:

• Immunology
• Oncology
• Proteomics

Background:

• Programmed death-ligand 1 (PD-L1) is crucial for tumor immune evasion, and its blockade is a key cancer therapy.
• Previous research focused on genomic and transcriptomic data, with limited proteomic analysis of PD-L1 signaling.

Purpose of the Study:

• To comprehensively analyze PD-1/PD-L1 signaling pathways across 12 cancer types at proteomic and transcriptomic levels.
• To identify novel biomarkers and predict response to anti-PD-1 immunotherapy.

Main Methods:

• Pan-cancer meta-analysis of proteomic and transcriptomic data from 12 human cancer types.
• Pathway-crosstalk analysis, immune-infiltration profiling, and protein-protein interaction network construction.
• Development and validation of a predictive biomarker signature for anti-PD-1 therapy response.

Main Results:

• Identified distinct cancer-type-specific PD-1/PD-L1 expression patterns.
• Revealed MMP9+ neutrophils as key immune subsets associated with PD-L1 activity.
• Discovered TAP proteins as potential biomarkers for small-cell lung cancer and established a predictive signature for non-small-cell lung cancer response to anti-PD-1 therapy.

Conclusions:

• PD-L1 expression and pathway activity are highly cancer-type specific.
• Proteomic and transcriptomic analyses offer valuable insights into PD-L1 biology and immunotherapy response.
• An interactive web tool is available for exploring PD-L1 features and associations.